BridgeBio Pharma, Inc. Marketable Securities (Non-Current)
BridgeBio Pharma, Inc. (BBIO) had Marketable Securities (Non-Current) of $60.69 million as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Balance Sheet › Assets
us-gaap:MarketableSecuritiesNoncurrent · last filed 2021-08-05
- 2021-06-30: Marketable Securities, Noncurrent $60.69M.
- 2021-03-31: Marketable Securities, Noncurrent $82.20M.
- 2020-03-31: Marketable Securities, Noncurrent $23.21M.
- 2019-12-31: Marketable Securities, Noncurrent $31.14M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2021-06-30 | $60.69M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $82.20M 10-Q · filed 2021-05-06 |
| 2020-03-31 | $23.21M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $31.14M 10-K · filed 2021-02-25 |
| 2019-09-30 | $75.89M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |